<DOC>
	<DOCNO>NCT01547897</DOCNO>
	<brief_summary>Primary objective : - To characterize effect 12 week treatment study drug albumin-creatinine ratio ( ACR ) patient type 2 diabetes albuminuria Secondary objective : - To characterize effect study drug glycosylated hemoglobin fraction ( HbA1c ) - To evaluate effect study drug marker glycemic disorder , systemic inflammation , renal liver disease cardiovascular function - To assess safety tolerability study drug - To determine population pharmacokinetics ( PK ) study drug</brief_summary>
	<brief_title>NOX-E36 Patients With Type 2 Diabetes Mellitus Albuminuria</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<criteria>1 . Type 2 diabetes mellitus accord American Diabetes Association ( ADA ) definition 2 . Age ≥ 18 3 . HbA1c 6.0 % 10.5 % , inclusive 4 . ACR &gt; 100 mg/g calculate 3 time first morning void urine , least 2 measurement &gt; 100 mg/g 5 . Patients stable ( unchanged medication least 3 month ) treatment control hypertension , hyperglycemia ( applicable ) dyslipidemia 6 . Stable treatment angiotensinconverting enzyme inhibitor ( ACEi ) and/or Angiotensin II receptor blocker ( ARBs ) ( reninangiotensin system [ RAS ] blockade ) 7 . Willing able understand sign approve Informed Consent form 8 . Men must agree follow accepted birth control method treatment 3 month completion treatment . Women must nonchildbearing potential . 1 . Type 1 diabetes mellitus 2 . Estimated Glomerular Filtration Rate ( eGFR ) ≤25 mL/min/1.73m2 ( calculate Chronic Kidney Disease Epidemiology Collaboration [ CKDEPI ] formula ) 3 . Recent cardiovascular event ( 3 month ) 4 . Uncontrolled hypertension ( upper limit 180/110 mmHg ) 5 . Dialysis and/or acute kidney injury within 3 month screen 6 . Significant edema , infectious disease , leg ulcer 7 . Severe concurrent disease , judgment investigator , would interfere significantly assessment safety efficacy study 8 . Treatment investigational agent , participation another clinical study within 90 day prior baseline visit 9 . Patient known infection human immunodeficiency virus ( HIV ) , Hepatitis B Hepatitis C 10 . In judgment clinical investigator , clinically significant abnormal laboratory value screen visit 11 . Use thiazolidinedione class drug , immune suppressant , steroid therapy ( except topical use inhalation ) , chronic use nonsteroidal antiinflammatory drug ( NSAIDs ) , cyclooxygenase type 2 ( COX2 ) inhibitor , two diuretic drug and/or aliskiren 12 . In judgment clinical investigator , patient likely noncompliant uncooperative study . 13 . Previous participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>